General Information of Drug (ID: DMFC0ZB)

Drug Name
PF-07242813 Drug Info
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMFC0ZB

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
T-cell surface glycoprotein CD1a (CD1A) TTBGTFN CD1A_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
T-cell surface glycoprotein CD1a (CD1A) DTT CD1A 6.528 6.589 6.534 6.615
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Atopic dermatitis
ICD Disease Classification EA80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
T-cell surface glycoprotein CD1a (CD1A) DTT CD1A 6.30E-02 0.67 1.48
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04668066) A PHASE 1 FIRST IN HUMAN, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF 07242813 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Pfizer